Novartis wins FDA approval for Cosentyx in polymyalgia rheumatica

On November 17, 2026, the U.S. Food and Drug Administration approved Novartis' Cosentyx 150 mg for adults with polymyalgia rheumatica who respond inadequately to corticosteroids or cannot tolerate steroid tapering. The approval is Cosentyx's 11th U.S. indication and makes it the first and only anti-IL-17 biologic approved for PMR. In the Phase III REPLENISH trial, sustained remission at Week 52 reached 40.5% with Cosentyx versus 20.5% with placebo after a 24-week steroid taper.

The decision expands Cosentyx's U.S. label into PMR and gives physicians an approved alternative to prolonged corticosteroid treatment. Novartis said regulatory reviews are also ongoing in other markets, including Japan, while the indication is already approved in the European Union.

  • 1The FDA approval covers Cosentyx 150 mg for adults with PMR who have had an inadequate response to corticosteroids or cannot tolerate corticosteroid tapering.
  • 2The approval represents Cosentyx's 11th indication in the United States.
  • 3In REPLENISH, sustained remission at Week 52 was 40.5% with Cosentyx 150 mg versus 20.5% with placebo after a 24-week steroid taper.
  • 4The REPLENISH trial evaluated patients across 27 countries.
  • 5Serious adverse events occurred in 15.9% of the Cosentyx 150 mg group and 14.2% of the placebo group.

Sources